On the contrary, the bile acid analog OCA dose-dependently increases FGF19 concentrations and, in parallel, decreases C4 concentrations in systemic blood of NAFLD subjects [33], suggesting a FGF19-dependent inhibition of bile acid synthesis. Here, FGF19 is linked to metabolic dysfunction-associated steatotic liver disease.